Image For Activity Cover
Nonpharmacological Management of ADHD



Emerging Topics Webinar Series

Stay up to date on important topics and trends impacting psychiatry by participating in APA's new Emerging Topics Webinar Series. Presented by specialists across the field, these monthly webinars will explore a range of diverse, pertinent topics and offer a chance to interact with peers and subject matter experts. 


This practical review summarizes highlights of ingestible and noningestible non-pharmacological treatments for ADHD, ranging from evidence-based conventional behavioral treatments to risky ones that should be restricted to specific indications. In between are numerous treatments, most of which are often referred to as complementary and alternative, that have promising but often inconclusive evidence. Principles for judging the evidence will be outlined. A method of deciding clinical applicability will be explained, with advice whether to encourage, discourage, or tolerate a treatment desired by a patient or family


Recorded webinar

Learning Objectives

  • To understand the widely varying evidence base for the broad array of nonpharmacological treatments for ADHD.
  • To distinguish evidence-based treatments from promising from risky unsupported treatments.
  • To devise a practical strategy for responsible clinical application of nonpharmacological treatments in the absence of conclusive evidence pro or con, using the SECS v. RUDE principle.


  • 1 hours of content
  • 30 minutes of Q and A


  • Sibley, M.H., Bruton, A.M, Zhao, X., Johnstone, J.M., Mitchell, J.T., Hatsu, I., Arnold, L.E., Basu, H.H., Levy, L., Vyas, P., Macphee, F., Schoenfelder Gonzalez, E., Kelley, M., Jusko, M.L., Bolden, C.R., Zulauf-McCurdy, C., Manzano, M., & Torres, G. (in press, 2022). Non-Pharmacological Interventions for Attention Deficit/Hyperactivity Disorder in Children and Adolescents: Update of the Evidence. Lancet Child & Adolescent Health.

    2. Johnstone JM, Hatsu I, Tost G, Srikanth P, Eiterman L, Bruton A, Ast H, Robinette L, Stern M, Millington E, Gracious B, Hughes A, Leung B MY, Arnold LE (In Press). Micronutrients for Attention-Deficit/Hyperactivity Disorder in Youth: A Placebo-Controlled Randomized Clinical Trial. Journal of the American Academy of Child and Adolescent Psychiatry.

    3. Neurofeedback Collaborative Group (incl. LE Arnold). Double-Blind Placebo-Controlled Randomized Clinical Trial of Neurofeedback for Attention-Deficit/Hyperactivity Disorder With 13 Month Follow-up. J. Amer. Acad. Child & Adolesc. Psychiatry, 2021; 60(7);841-


    4. The Neurofeedback Collaborative Group: Arnold L.E., Arns A, Barterian J, Connor S, deBeus R, Hollway J, Kerson C, Kraemer HC, Lightstone H, Lubar J, McBurnett K, Monastra V, Mulligan A, Buchan-Page K, Pan X(J), Rice R, Roley-Roberts M, Schrader C, Tan Y,. Williams CE. Neurofeedback for ADHD: 25-month follow-up of double-blind randomized controlled trial (2022). Journal of American Academy of Child & Adolescent Psychiatry. In press, 2022.

    5. Robinette, LM; Hatsu, I; Johnstone JM; Tost, G; Bruton, AM; Eiterman, LP; Leung, BMY; Odie, JB; Orchard, T; Gracious, BL; Arnold, LE. Fruit and Vegetable Intake is Inversely Associated with Severity of Inattention in a Pediatric Population with ADHD Symptoms: The MADDY Study. Nutr Neurosci. 2022. 2022 May 10:1-10. doi: 10.1080/1028415X.2022.2071805. PMID: 35535573.

Target Audience

Medical students, Residents/Fellows, Psychiatrists, Social Workers

Estimate Time to Complete

Estimated Duration: 1.5 hours
Program Start Date: August 17, 2023
Program End Date: August 17, 2026


How to Earn Credit

After evaluating the program, participants will be provided with an opportunity to claim hours of participation and print an official CME certificate (physicians) or certificate of participation (non-physicians) showing the event date and hours earned.

Continuing Education Credit

In support of improving patient care, the American Psychiatric Association is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.


The APA designates this enduring activity for a maximum of 1.5 AMA PRA Category 1 Credit ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Faculty and Planner Disclosures

The American Psychiatric Association adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Medical Education. Any individuals in a position to control the content of a CME activity — including faculty, planners, reviewers or others — are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.


  • L. Eugene Arnold, MD, MEd. Reports financial relationships with Axial, Yamo, Maplight, Otsuka, Roche/Genetech, and Myndlift.


  • Vishal Madaan, MD, Chief of Education, APA, has no relevant financial relationships to disclose.

Accessibility for Participants with Disabilities

The American Psychiatric Association is committed to ensuring accessibility of its website to people with disabilities. Please contact the American Psychiatric Association at 202-559-3900, if you require assistance seven (7) business days prior to the start of a live webinar.

Technical Requirements

This internet-based CME activity is best experienced using any of the following:

  • The latest and 2nd latest public versions of Google Chrome, Mozilla Firefox, or Safari
  • Internet Explorer 11+

This Web site requires that JavaScript and session cookies be enabled. Certain activities may require additional software to view multimedia, presentation, or printable versions of the content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Acrobat Reader, Microsoft PowerPoint, and Windows Media Player.

Optimal System Configuration:

  • Browser: Google Chrome (latest and 2nd latest version), Safari (latest and 2nd latest version), Internet Explorer 11.0+, Firefox (latest and 2nd latest version), or Microsoft Edge (latest and 2nd latest version)
  • Operating System: Windows versions 8.1+, Mac OS X 10.5 (Leopard) +, Android (latest and 2nd latest version), or iOS/iPad OS (latest and 2nd latest version)
  • Internet Connection: 1 Mbps or higher

Minimum Requirements:

  • Windows PC: Windows 8.1 or higher; 1 GB (for 32-bit)/2 GB (for 64-bit) or higher RAM; Microsoft DirectX 9 graphics device with WDDM driver; audio playback with speakers for programs with video content
  • Macintosh: Mac OS X 10.5 or higher with latest updates installed; Intel, PowerPC G5, or PowerPC G4 (867MHz or faster) processor; 512 MB or higher RAM; audio playback with speakers for programs with video content

For assistance: Contact for questions about this activity

Availability: On-Demand
Expires on 08/17/2026
Cost: $50.00
Credit Offered:
1.5 CME Credits
1.5 COP Credits
Powered By